Overview

Viscoelastic Testing Guided Tissue Plasminogen Activator Treatment in Acute Respiratory Failure

Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
Patients with coronavirus disease (COVID) and non-COVID acute respiratory failure (ARF) may be at an increased risk of thrombosis due to increased clot formation and decreased clot lysis. This two stage study aims to utilise bedside coagulation technology to detect patients at increased risk and guide tPA treatment to maximise efficacy and safety through a personalised approach.
Phase:
Phase 2
Details
Lead Sponsor:
South West Sydney Local Health District
Treatments:
Plasminogen
Tissue Plasminogen Activator